Home > Newsletters > Drug Industry Daily > Bapineuzumab Trial Failure May Signal Bleak Outlook for New Alzheimer’s Drugs
Drug Industry Daily
Aug. 8, 2012 | Vol. 11 No. 155
Bapineuzumab Trial Failure May Signal Bleak Outlook for New Alzheimer’s Drugs
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.